Impact of Cooperative Microfinance on the Performance of Women Entrepreneurship in Kwara State Nigeria

This study assessed the effect of cooperative microfinance on the performance of women entrepreneurship in Kwara State, Nigeria. Specifically, the study identified entrepreneurial activities carried out by the women entrepreneurs, contributions of co-operative entrepreneurial activities to the women as well as identified constraints experienced by the cooperators in developing entrepreneurship among members

Entropy for Asymptotically AdS_3 Black Holes

We propose that Strominger's method to derive the BTZ black hole entropy is in fact applicable to other asymptotically AdS_3 black holes and gives the correct functional form of entropies. We discuss various solutions in the Einstein-Maxwell theory, dilaton gravity, Einstein-scalar theories, and Einstein-Maxwell-dilaton theory. In some cases, solutions approach AdS_3 asymptotically, but their entropies do not have the form of Cardy's formula. However, it turns out that they are actually not "asymptotically $AdS_3$" solutions. On the other hand, for truly asymptotically AdS_3 solutions, their entropies have the form of Cardy's formula. In this sense, all known solutions are consistent with our proposal.Comment: 21 pages, LaTeX; v2: added discussion for section 3.

Ionizing radiation absorption of vascular surgeons during endovascular procedures

ObjectiveEndovascular procedures have become an integral part of a vascular surgeon’s practice. The exposure of surgeons to ionizing radiation and other safety issues have not been well studied. We investigated the radiation exposure of a team of vascular surgeons in an active endovascular unit and compared yearly dosages absorbed by various body parts among different surgeons. Patients’ radiation exposure was also assessed.MethodsThe radiation absorption of a team of vascular surgeons was prospectively monitored in a 12-month period. During each endovascular procedure, the effective body, eye, and hand radiation doses of all participating surgeons were measured by mini-thermoluminescent dosimeters (TLD) attached at the chest level under a lead apron, at the forehead at eye level, and at the hand. The type of procedure, fluoroscopy machine, fluoroscopy time, and personal and operating theatre radiation protection devices used in each procedure were also recorded. One TLD was attached to the patient’s body near the operative site to measure the patient’s dose. The yearly effective body, eye, and hand dose were compared with the safety limits of radiation for occupational exposure recommended by the International Commission on Radiation Protection (ICRP). The radiation absorption of various body parts per minute of fluoroscopy was compared among different surgeons.ResultsA total of 149 consecutive endovascular procedures were performed, including 30 endovascular aortic repairs (EVAR), 58 arteriograms with and without embolization (AGM), and 61 percutaneous transluminal angioplasty and stent (PTA/S) procedures. The cumulative fluoroscopy time was 1132 minutes. The median yearly effective body, eye, and hand dose for the surgeons were 0.20 mSv (range, 0.13 to 0.27 mSv), 0.19 mSv (range, 0.10 to 0.33 mSv) and 0.99 mSv (0.29 to 1.84 mSv) respectively, which were well below the safety limits of the ICRP. The mean body, eye, and hand dose of the chief surgeon per procedure were highest for EVAR. A significant discrepancy was observed for the average hand dose per minute of fluoroscopy among different surgeons. The mean radiation absorption of patients who underwent EVAR, AGM, and PTA/S was 12.7 mSv, 13.6 mSv, and 3.4 mSv, respectively.ConclusionWith current radiation protection practice, the radiation absorbed by vascular surgeons with a high endovascular workload did not exceed the safety limits recommended by ICRP. Variations in practice, however, can result in significant discrepancy of radiation absorption between surgeons

Effects of Replacing Soybean (Glycine Max) with Fermented Sickle Pod (Senna Obtusifolia) on the Productive Performance and Carcass Characteristics of Domestic Rabbits

An experiment was conducted for 56 days to determine the productive performance and carcass characteristics of domestic rabbits fed fermented Senna obtusifolia seed meal (FSOSM)-based diets. A control soybean meal-based diet and diets containing 0, 25, 50, 75 and 100% FSOSM as a replacement for soybean were formulated for the study. Twenty (20) domestic growing rabbits with an initial weight range of 605.25 – 662.75 g were randomly allotted to the five dietary treatments in a Completely Randomized Block Design with four replicates of one rabbit each. The productive performance was not significantly (P < 0.05) influenced by the diets. The daily weight gain ranged from 11.11 – 12.09 g/d, total weight gain 622.16 – 677.01 g/d, daily feed intake 55.15 – 61.41 g and feed conversion ratio ranged from 4.83 – 5.02. The carcass characteristics were similarly not affected (P < 0.05) by the dietary treatments. Dressing percentage ranged from 50.05 – 59.70% and retail cuts for shoulder, rack, loin and thigh were 17.73 – 18.99, 5.20 – 6.28, 13.26 – 14.17 and 20.28 – 22.33 percent body weight. It was concluded from this study that replacement of soybean with FSOSM up to 100% had no adverse effects on the productive parameters and carcass characteristics of domestic rabbits

Classtalk: A Classroom Communication System for Active Learning

This pdf file is an article describing the advantages of using Classtalk technology in the classroom to enhance classroom communication. Classtalk technology cab facilitate the presentation of questions for small group work, collec the student answers and then display histograms showing how the class answered. This new communication technology can help instructors create a more interactive, student centered classroom, especially when teaching large courses. The article describes Classtalk as a very useful tool not only for engaging students in active learning, but also for enhancing the overall communication within the classroom. This article is a selection from the electronic Journal for Computing in Higher Education. Educational levels: Graduate or professional

Controlling enantioselectivity of limonene synthases by exploring natural diversity combined to molecular engineering

Please click Additional Files below to see the full abstrac

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study

Background: Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has shown evidence of additive activity in several tumor types. This phase III study evaluated the efficacy of durvalumab (an anti-PD-L1 monoclonal antibody) or durvalumab plus tremelimumab (an anti-CTLA-4 monoclonal antibody) versus standard of care (SoC) in R/M HNSCC patients. Patients and methods: Patients were randomly assigned to receive 1 : 1 : 1 durvalumab (10 mg/kg every 2 weeks [q2w]), durvalumab plus tremelimumab (durvalumab 20 mg/kg q4w plus tremelimumab 1 mg/kg q4w 4, then durvalumab 10 mg/kg q2w), or SoC (cetuximab, a taxane, methotrexate, or a fluoropyrimidine). The primary end points were overall survival (OS) for durvalumab versus SoC, and OS for durvalumab plus tremelimumab versus SoC. Secondary end points included progression-free survival (PFS), objective response rate, and duration of response. Results: Patients were randomly assigned to receive durvalumab (n 1⁄4 240), durvalumab plus tremelimumab (n 1⁄4 247), or SoC (n 1⁄4 249). No statistically significant improvements in OS were observed for durvalumab versus SoC [hazard ratio (HR): 0.88; 95% confidence interval (CI): 0.72e1.08; P 1⁄4 0.20] or durvalumab plus tremelimumab versus SoC (HR: 1.04; 95% CI: 0.85e1.26; P 1⁄4 0.76). The 12-month survival rates (95% CI) were 37.0% (30.9e43.1), 30.4% (24.7e36.3), and 30.5% (24.7 e36.4) for durvalumab, durvalumab plus tremelimumab, and SoC, respectively. Treatment-related adverse events (trAEs) were consistent with previous reports. The most common trAEs (any grade) were hypothyroidism for durvalumab and durvalumab plus tremelimumab (11.4% and 12.2%, respectively), and anemia (17.5%) for SoC. Grade !3 trAE rates were 10.1%, 16.3%, and 24.2% for durvalumab, durvalumab plus tremelimumab, and SoC, respectively. Conclusion: There were no statistically significant differences in OS for durvalumab or durvalumab plus tremelimumab versus SoC. However, higher survival rates at 12 to 24 months and response rates demonstrate clinical activity for durvalumab

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

BACKGROUND: Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting molecular heterogeneity of the disease. We compared two different, single-modality treatment strategies of standard radiotherapy versus primary temozolomide chemotherapy in patients with low-grade glioma, and assessed progression-free survival outcomes and identified predictive molecular factors. METHODS: For this randomised, open-label, phase 3 intergroup study (EORTC 22033-26033), undertaken in 78 clinical centres in 19 countries, we included patients aged 18 years or older who had a low-grade (WHO grade II) glioma (astrocytoma, oligoastrocytoma, or oligodendroglioma) with at least one high-risk feature (aged &gt;40 years, progressive disease, tumour size &gt;5 cm, tumour crossing the midline, or neurological symptoms), and without known HIV infection, chronic hepatitis B or C virus infection, or any condition that could interfere with oral drug administration. Eligible patients were randomly assigned (1:1) to receive either conformal radiotherapy (up to 50·4 Gy; 28 doses of 1·8 Gy once daily, 5 days per week for up to 6·5 weeks) or dose-dense oral temozolomide (75 mg/m(2) once daily for 21 days, repeated every 28 days [one cycle], for a maximum of 12 cycles). Random treatment allocation was done online by a minimisation technique with prospective stratification by institution, 1p deletion (absent vs present vs undetermined), contrast enhancement (yes vs no), age (&lt;40 vs ≥40 years), and WHO performance status (0 vs ≥1). Patients, treating physicians, and researchers were aware of the assigned intervention. A planned analysis was done after 216 progression events occurred. Our primary clinical endpoint was progression-free survival, analysed by intention-to-treat; secondary outcomes were overall survival, adverse events, neurocognitive function (will be reported separately), health-related quality of life and neurological function (reported separately), and correlative analyses of progression-free survival by molecular markers (1p/19q co-deletion, MGMT promoter methylation status, and IDH1/IDH2 mutations). This trial is closed to accrual but continuing for follow-up, and is registered at the European Trials Registry, EudraCT 2004-002714-11, and at ClinicalTrials.gov, NCT00182819. FINDINGS: Between Sept 23, 2005, and March 26, 2010, 707 patients were registered for the study. Between Dec 6, 2005, and Dec 21, 2012, we randomly assigned 477 patients to receive either radiotherapy (n=240) or temozolomide chemotherapy (n=237). At a median follow-up of 48 months (IQR 31-56), median progression-free survival was 39 months (95% CI 35-44) in the temozolomide group and 46 months (40-56) in the radiotherapy group (unadjusted hazard ratio [HR] 1·16, 95% CI 0·9-1·5, p=0·22). Median overall survival has not been reached. Exploratory analyses in 318 molecularly-defined patients confirmed the significantly different prognosis for progression-free survival in the three recently defined molecular low-grade glioma subgroups (IDHmt, with or without 1p/19q co-deletion [IDHmt/codel], or IDH wild type [IDHwt]; p=0·013). Patients with IDHmt/non-codel tumours treated with radiotherapy had a longer progression-free survival than those treated with temozolomide (HR 1·86 [95% CI 1·21-2·87], log-rank p=0·0043), whereas there were no significant treatment-dependent differences in progression-free survival for patients with IDHmt/codel and IDHwt tumours. Grade 3-4 haematological adverse events occurred in 32 (14%) of 236 patients treated with temozolomide and in one (&lt;1%) of 228 patients treated with radiotherapy, and grade 3-4 infections occurred in eight (3%) of 236 patients treated with temozolomide and in two (1%) of 228 patients treated with radiotherapy. Moderate to severe fatigue was recorded in eight (3%) patients in the radiotherapy group (grade 2) and 16 (7%) in the temozolomide group. 119 (25%) of all 477 patients had died at database lock. Four patients died due to treatment-related causes: two in the temozolomide group and two in the radiotherapy group. INTERPRETATION: Overall, there was no significant difference in progression-free survival in patients with low-grade glioma when treated with either radiotherapy alone or temozolomide chemotherapy alone. Further data maturation is needed for overall survival analyses and evaluation of the full predictive effects of different molecular subtypes for future individualised treatment choices. FUNDING: Merck Sharpe &amp; Dohme-Merck &amp; Co, Canadian Cancer Society, Swiss Cancer League, UK National Institutes of Health, Australian National Health and Medical Research Council, US National Cancer Institute, European Organisation for Research and Treatment of Cancer Cancer Research Fund

Horizontal Branch Stars: The Interplay between Observations and Theory, and Insights into the Formation of the Galaxy

We review HB stars in a broad astrophysical context, including both variable and non-variable stars. A reassessment of the Oosterhoff dichotomy is presented, which provides unprecedented detail regarding its origin and systematics. We show that the Oosterhoff dichotomy and the distribution of globular clusters (GCs) in the HB morphology-metallicity plane both exclude, with high statistical significance, the possibility that the Galactic halo may have formed from the accretion of dwarf galaxies resembling present-day Milky Way satellites such as Fornax, Sagittarius, and the LMC. A rediscussion of the second-parameter problem is presented. A technique is proposed to estimate the HB types of extragalactic GCs on the basis of integrated far-UV photometry. The relationship between the absolute V magnitude of the HB at the RR Lyrae level and metallicity, as obtained on the basis of trigonometric parallax measurements for the star RR Lyrae, is also revisited, giving a distance modulus to the LMC of (m-M)_0 = 18.44+/-0.11. RR Lyrae period change rates are studied. Finally, the conductive opacities used in evolutionary calculations of low-mass stars are investigated. [ABRIDGED]Comment: 56 pages, 22 figures. Invited review, to appear in Astrophysics and Space Scienc